Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL

James K. McCloskey II, MD
Published: Thursday, Dec 21, 2017



James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia (ALL).

CD19 is an ideal target in B-cell ALL, says McCloskey, as it is expressed on the surface of the cells of these patients.

The antibody-drug conjugate loncastuximab tesirine (ADCT-402), which is designed to target CD19, is currently being evaluated in patients with relapsed or refractory B-cell ALL.
 


James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia (ALL).

CD19 is an ideal target in B-cell ALL, says McCloskey, as it is expressed on the surface of the cells of these patients.

The antibody-drug conjugate loncastuximab tesirine (ADCT-402), which is designed to target CD19, is currently being evaluated in patients with relapsed or refractory B-cell ALL.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x